News Medical Research
Avicanna sponsors new medical cannabis education and training campaign in Canada

(Globe Newswire) Toronto — Avicanna Inc., a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, has entered into a sponsorship agreement with the Canadian Consortium for the Investigation of Cannabinoids (CCIC) to sponsor CICC in making available and providing access to the Canadian Cannabis Syllabus (CCS), continuing education course accredited by the University of Calgary’s Office of Continuing Medical Education and Professional Development, available to the Canadian medical community.

“We are proud to be sponsoring CCIC who have championed the advancement of evidence-based research and education on the endocannabinoid system in Canada. In line with the launch of MyMedi.ca and our commitment to advance medical cannabis access, we believe that the CCS can be an effective tool to provide education for healthcare providers and provide information to support the adoption of medical cannabis by the medical community.” — Dr. Karolina Urban, EVP of medical affairs, Avicanna Inc.

“The CCIC is excited to develop this relationship with Avicanna as it will help to ensure the dissemination of accurate, scientifically valid and vetted information regarding the biology of cannabis and how it impacts the human body, potential therapeutic approaches that cannabis and cannabinoid products could be leveraged for with respect to specific disease states and putative health risks associated with cannabis use and the development of cannabis use disorder.” — Dr. Matthew Hill, executive director, CCIC

Through the sponsorship agreement the CCS will be offered to healthcare providers interested in learning more about medical cannabis as a part of their practice. The CCS provides foundational knowledge and considerations for all healthcare professionals interested in learning more about cannabis and cannabinoid products in clinical practice.